Zoccali C
Epidemiologia Clinica e Fisiopatologia delle malattie Renali e dell'Ipertensione Arteriosae Unita Operativa di Nefrologia, Dialisi e Trapianto Renale, Ospedali Riuniti, Reggio Calabria, Italy.
Kidney Int. 2006 Dec;70(12):2053-5. doi: 10.1038/sj.ki.5001898.
The nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) is an emerging risk biomarker in cardiovascular and renal diseases. Apparently amlodipine and valsartan produce substantial reductions in the plasma concentration of this methylarginine in hemodialysis patients. These findings are of relevance for designing studies aimed at testing the etiologic relevance of ADMA to the high cardiovascular risk of ESRD.
一氧化氮合酶抑制剂不对称二甲基精氨酸（ADMA）是心血管疾病和肾脏疾病中一种新出现的风险生物标志物。显然，氨氯地平和缬沙坦可使血液透析患者血浆中这种甲基精氨酸的浓度大幅降低。这些发现对于设计旨在检验ADMA与终末期肾病高心血管风险之间病因学关联的研究具有重要意义。
